Next, we evaluated the effect of EFR3A/B loss on the KRAS signaling and transformation in a rare KRAS mutation-negative human pancreatic adenocarcinoma cell line, finding that EFR3A and/or EFR3B sgRNA had little to no effect on the levels of P-ERK or P-AKT (Supplementary Fig. 4b), 2D- (Supplementary Fig. 4c, d), and 3D- (Supplementary Fig. 4a) transformed growth. Here, EFR3A is linked to pancreatic adenocarcinoma.